Fulgent Genetics Inc (FLGT)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 36.42% | 34.08% | 37.06% | 36.10% | 35.44% | 32.20% | 32.03% | 39.24% | 59.28% | 67.68% | 73.69% | 77.01% | 78.29% | 80.19% | 79.34% | 79.33% | 78.70% | 69.16% | 55.90% | 56.47% |
| Operating profit margin | -26.08% | -31.92% | -24.55% | -25.13% | -26.03% | -28.28% | -26.23% | -11.58% | 29.81% | 46.32% | 57.36% | 64.08% | 68.10% | 72.50% | 72.03% | 72.28% | 68.80% | 47.25% | 4.17% | -1.49% |
| Pretax margin | -18.33% | -68.09% | -56.32% | -58.15% | -60.19% | -21.77% | -21.94% | -10.69% | 29.73% | 45.87% | 56.89% | 64.20% | 68.24% | 72.69% | 72.23% | 72.48% | 69.17% | 48.12% | 6.35% | 1.01% |
| Net profit margin | -15.07% | -59.39% | -56.22% | -57.71% | -58.20% | -22.44% | -16.21% | -7.41% | 23.07% | 33.78% | 42.41% | 48.32% | 51.12% | 54.96% | 54.24% | 53.91% | 50.82% | 35.31% | 5.78% | -1.31% |
Fulgent Genetics Inc's gross profit margin has exhibited fluctuations over the analyzed period, starting at a robust 56.47% in March 2020, peaking at 80.19% in September 2021, then declining to 36.42% by December 2024.
The operating profit margin shows a more volatile trend, ranging from -1.49% in March 2020 to a high of 72.50% in September 2021, before dropping significantly to -31.92% in September 2024.
Similarly, the pretax margin has experienced fluctuations, with a peak of 72.69% in September 2021 and a low of -68.09% in September 2024.
In terms of net profit margin, Fulgent Genetics Inc saw positive margins in the earlier years, reaching a high of 54.96% in September 2021. However, the margins turned negative in the later periods, with December 2024 showing a net profit margin of -15.07%.
Overall, while Fulgent Genetics Inc demonstrated strong profitability in the initial years, there has been a notable decline in profitability margins in the latter periods, highlighting potential challenges faced by the company in maintaining profitability.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -6.06% | -7.19% | -5.79% | -5.88% | -5.91% | -5.96% | -5.95% | -3.07% | 13.31% | 26.46% | 36.30% | 41.69% | 52.86% | 62.34% | 62.41% | 55.95% | 41.42% | 25.81% | 1.90% | -0.58% |
| Return on assets (ROA) | -3.50% | -13.37% | -13.26% | -13.49% | -13.22% | -4.73% | -3.68% | -1.96% | 10.30% | 19.29% | 26.84% | 31.43% | 39.68% | 47.26% | 47.00% | 41.73% | 30.60% | 19.29% | 2.64% | -0.51% |
| Return on total capital | -6.65% | -8.14% | -5.94% | -6.36% | -6.90% | -6.21% | -6.60% | -3.33% | 14.40% | 28.63% | 40.09% | 45.85% | 57.64% | 72.06% | 70.87% | 69.73% | 50.96% | 34.15% | 2.10% | -0.64% |
| Return on equity (ROE) | -3.77% | -14.49% | -14.43% | -14.69% | -14.82% | -5.11% | -3.95% | -2.13% | 11.24% | 21.16% | 30.07% | 35.08% | 43.52% | 54.91% | 53.59% | 52.02% | 37.64% | 25.52% | 2.91% | -0.56% |
The profitability ratios of Fulgent Genetics Inc show a fluctuating trend over the past few years.
- Operating Return on Assets (Operating ROA): Despite significant volatility, the company demonstrated a positive trend from negative values in early 2020 to a peak of around 62.41% in mid-2021. However, there has been a decline in profitability since then, with the ratio dropping to around -7.19% by the end of 2024.
- Return on Assets (ROA): Similar to Operating ROA, ROA also started from negative values in early 2020, reached its highest point of around 47.26% in late 2021, and then decreased to around -13.37% by the end of 2024, reflecting a less favorable performance in recent periods.
- Return on Total Capital: The Return on Total Capital ratio followed a similar trajectory, with a peak of around 72.06% in late 2021 and a decrease to approximately -8.14% by the end of 2024, indicating a worsening profitability trend over the last few years.
- Return on Equity (ROE): The ROE exhibited a pattern in line with the other profitability ratios, peaking around 54.91% in late 2021 before declining to approximately -14.49% by the end of 2024, highlighting a substantial decrease in overall profitability and return for the company's shareholders.
Overall, Fulgent Genetics Inc's profitability ratios show a mixed performance, with periods of strong profitability followed by declining returns and challenges to maintain consistent profitability levels in recent years.